tbuckley/cabot-search huggingface dataset:
A FNCLCC French Sarcoma Group—GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS)
Authors: F. Duffaud, B. N. Bui, N. Penel, A. Cioffi, N. Isambert, J. Y. Blay, D. Cupissol, M. Jimenez, A. Rey, P. Pautier
Journal: Journal of Clinical Oncology (2008)

10511 Background: We sought to determine the response of metastatic or relapsed LMS to G vs. G+D in a randomized multicenter phase II study initiated before the completion of a recently reported trial (JCO 2007 Maki.) Methods: Eligible patients have histologically proven leiomyosarcoma, metastatic LMS or with unresectable local relapse, one prior anthracycline-based regimen, age ≥18, measurable disease (RECIST criteria), PS ≤ 2, adequate organ function. Treatment is G 1,000 mg/m2 (over 100 minutes, d1+d8+d15) q28 days or G 900 mg/m2 (over 90 min, d1+d8) and docetaxel 100 mg/m2 (over 60 min, d8) q21 days; in the G+D arm, all patients receive lenograstim from day 9 to day 15, 25% dose reductions are employed for prior pelvic radiation. Tumoral evaluation is done every 2 cycles. The primary endpoint is the objective tumor response rate (CR+PR). At randomization, stratification is done by primary tumor location (uterus vs. soft tissue). Each stratum is considered as an independent phase II study. The Simon method was used to calculate the number of patients: for "uterus" study, 20 evaluable pts per arm for a 74% probability of selecting the arm that has a true response rate (RR) of 50%, the expected baseline RR is 40%. For the "non-uterus" study, 20 evaluable pts per arm for a 91,8% probability of selecting the arm that has a true RR of 40%, the expected baseline RR is 20%. Results: From 02/06 to 12/07, 40 pts were enrolled in the "non-uterus" study, 25 pts in the "uterus" study. Currently 58/65 pts are evaluable (35/40 in the "non-uterus" and 23/25 in the "uterus" study) and 64/65 are assessable for toxicity. The median age is 64 (range 29–78) for soft tissue and 56 (range 41–80) for uterus, the median number of cycles is 4 (range 0 to 8). In the G arm, toxicity is moderate. In the G+D arm one toxic death related to G5 thrombocytopenia occurred, 1 pt stopped treatment for G3 thrombocytopenia and 5 pts for non- hematologic toxicities. Conclusions: Final tumor response and toxicity results will be presented during the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline, Novartis, Pfizer, PharmaMar GlaxoSmithKline, Novartis, Pfizer, PharmaMar Chugai, Novartis
MIR-21 Inhibition and Obeticholic Acid Ameliorate Non-Alcoholic Steatohepatitis in Dietary Animal Models
Authors: P.M. Rodrigues, M.B. Afonso, A.L. Simão, M. Caridade, C.C. Carvalho, A. Trindade, A. Duarte, P.M. Borralho, M.V. Machado, H. Cortez-Pinto, C.M.P. Rodrigues, R.E. Castro
Journal: Journal of Hepatology (2016)
Decitabine Act As Demethylation Modulators in Acute Myeloid Leukemia for Reversal of Drug Resistance
Authors: Zhixiang Wang, Xuejie Jiang, Kaikai Huang, Changxin Yin, Qingxiu Zhong, Qiuhua Zhu, Bingjie Ding, Fan Yi Meng
Journal: Blood (2014)
Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1A and GT1B-Infected Patients
Authors: C. Sarrazin, M.S. Sulkowski, P. Krishnan, R. Tripathi, G. Schnell, Y. Xie, D.E. Cohen, R. Trinh, L. Rodrigues, Y. Luo, N.S. Shulman, T. Pilot-Matias, C. Collins
Journal: Journal of Hepatology (2016)
Analysis of Hepatitis B Surface Antigen (HBsAg) Levels Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Hepatitis B Virus Patients with HBsAg Seroclearance According to the Conventional Assay
Authors: I. Ozeki, T. Nakajima, S. Hige, Y. Karino, J. Toyota
Journal: Journal of Hepatology (2016)
Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania
Authors: G.G. Di Costanzo, M. Guarino, G. De Stefano, C. Coppola, R. Tortora, F. Morisco, S.M. Angelo, F. Izzo, G. Nardone, G. Piai, L.E. Adinolfi, G. D’Adamo, G.B. Gaeta, V. Messina, G. Francica, V. De Girolamo, N. Coppola
Journal: Journal of Hepatology (2016)
Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease
Authors: Emmanuel J. Favaloro
Journal: American Journal of Hematology (2016)

von Willebrand Disease (VWD) is the most common inherited bleeding disorder and also arises as an acquired defect (AVWS). VWD and AVWS are due to quantitative deficiencies and/or qualitative defects in von Willebrand factor (VWF), an adhesive plasma protein with multiple activities. Diagnosis of VWD is problematic, being subject to overdiagnosis, underdiagnosis, and misdiagnosis. This is largely due to limitations in current test procedures and an over-reliance on these imperfect test systems for clinical diagnosis. VWF essentially acts to assist in the formation of a platelet thrombus to stop blood loss from sites of injury, achieving this by binding to platelets (primarily through the glycoprotein Ib receptor), binding to subendothelial matrix components (primarily collagen), and binding to factor VIII (FVIII), thus protecting FVIII from degradation and enabling its delivery to sites of vascular injury. VWD is classified into six separate types, which may each be differentially managed therapeutically, and this underscores the importance of a correct diagnosis. The current report concisely reviews the utility of a relatively underutilised assay, the VWF collagen binding assay (VWF:CB), in facilitating the correct diagnosis and typing of VWD. In particular, if laboratories do not utilise the VWF:CB, then (i) type 2M VWD will continue to be missed, and/or misdiagnosed as types 2A or 1 VWD, and (ii) types 2A, 2B and PT-VWD will continue to be missed, or else be misdiagnosed as type 1 VWD or ITP. Am. J. Hematol. 92:114-118, 2017. © 2016 Wiley Periodicals, Inc.
Embolization of spontaneous portosystemic shunts in cirrhotic patients with refractory hepatic encepalopathy : results of a single center prospective exploratory study
Authors: K Ameloot, Wim Laleman, Sam Heye, J Vaninbouckx, Chris Verslype, David Cassiman, Johan Fevery, Geert Maleux, Frederik Nevens
Journal: Hepatology (2011)
Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by α4β1/7 inhibition
Authors: Aimee G. Kim, Jesse D. Vrecenak, Matthew M. Boelig, Linda Eissenberg, Michael P. Rettig, John S. Riley, Matthew S. Holt, Michael A. Conner, Stavros P. Loukogeorgakis, Haiying Li, John F. DiPersio, Alan W. Flake, William H. Peranteau
Journal: Blood (2016)
Daily exercise prevents diastolic dysfunction and oxidative stress in a female mouse model of western diet induced obesity by maintaining cardiac heme oxygenase-1 levels
Authors: Brian Bostick, Annayya R. Aroor, Javad Habibi, William Durante, Lixin Ma, Vincent G. DeMarco, Mona Garro, Melvin R. Hayden, Frank W. Booth, James R. Sowers
Journal: Metabolism (2016)
Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
Authors: Anuradha Rao, Astrid Kosters, Jamie E. Mells, Wujuan Zhang, Kenneth D. R. Setchell, Angelica M. Amanso, Grace M. Wynn, Tianlei Xu, Brad T. Keller, Hong Yin, Sophia Banton, Dean P. Jones, Hao Wu, Paul A. Dawson, Saul J. Karpen
Journal: Science Translational Medicine (2016)

Inhibition of the ileal bile acid transporter treats multiple features of nonalcoholic steatohepatitis in high-fat diet–fed mice.
Codman, Hawthorne, and End Results of a Watched System
Authors: Jason M. Johanning, Shipra Arya
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Psychiatrist who was cleared by first tribunal is struck off
Authors: Clare Dyer
Journal: BMJ (2016)

A psychiatrist who initially escaped sanction for falsifying documents has been struck off the UK medical register after his case was sent back to the Medical Practitioners Tribunal Service (MPTS) by the High Court.

An MPTS decision in 2015 that Okwuolisa Igwilo’s fitness to practise was not impaired was overturned after a rare appeal to the High Court by the Professional Standards Authority for Health and Social Care. The authority successfully argued that …
Comparison of Treatment Outcome between Living Donor Liver Transplantation and Sorafenib for Patients with BCLC B or C Stage Hepatocellular Carcinoma
Authors: Y. Cho, J.-H. Lee, D.H. Lee, E.J. Cho, S.J. Yu, N.-J. Yi, K.-W. Lee, K.-S. Suh, Y.J. Kim, J.-H. Yoon
Journal: Journal of Hepatology (2016)
Response at First Chemoembolization is a Robust Predictor of Favorable Outcome in Hepatocellular Carcinoma
Authors: W. Teng, Y.-C. Hsieh, K.-W. Liu, C.-F. Hung, W.-J. Jeng, C.-H. Huang, W.-T. Chen, Y.-C. Chen, C.-C. Lin, C.-Y. Lin, S.-M. Lin, I.-S. Sheen
Journal: Journal of Hepatology (2016)
O091 : Oral therapy with non-absorbable carbons of controlled porosity (YAQ-001) selectively modulates stool microbiome and its function and this is associated with restoration of immune function and inflammasome activation
Authors: J. Macnaughtan, I. Ranchal, J. Soeda, R. Sawhney, J. Oben, N. Davies, R. Mookerjee, J. Marchesi, J. Cox, R. Jalan
Journal: Journal of Hepatology (2015)
Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.
Authors: Carmelo Carlo-Stella, Massimo Di Nicola, Paolo Longoni, Loredana Cleris, Marco Milanesi, Cristiana Lavazza, Raffaella Milani, Matteo Carrabba, Franca Formelli, Alessandro M. Gianni, Paolo Corradini
Journal: Blood (2004)
The Prevalence of Non-Alcoholic Steatohepatitis among Diabetic Patients Followed by Primary Care and Endocrinology
Authors: K. Joshi, J. Thakkar, A. Boron, A. Moore, A. Hepner, J. Deer, M. Rodriguez, R. Gish, J. Reynolds, R. Manch, A. Kohli
Journal: Journal of Hepatology (2016)
NICE issues guidance on inappropriate sexual behaviour in children
Authors: Ingrid Torjesen
Journal: BMJ (2016)

The display of inappropriate sexual behaviour by children and young people must be tackled and not ignored, the National Institute for Health and Care Excellence says in a new guideline on harmful sexual behaviour.1

While many young people who engage in sexual discussions or acts that are inappropriate for their age or development will grow out of these behaviours, evidence shows that early opportunities to recognise and deal with them were missed in some cases of the small number of young people who commit sexual …
Low Levels of Natural IGM Antibodies Towards Oxidation-Specific Epitopes are Associated with Human Non-Alcoholic Steatohepatitis
Authors: T. Hendrikx, M. Watzenboeck, S.M. Walenbergh, S. Kalhan, G.H. Koek, D. Jonkers, C.J. Binder, R. Shiri-Sverdlov
Journal: Journal of Hepatology (2016)
LFA1 Mediated Attachment of Primary Human Monocytes to Activated Brain Microvascular Endothelial Cells Is Regulated by SDF-1α through the SRC Family Kinase Lyn; Potential Involvement of This Signaling Pathway in HIV-Associated Dementia.
Authors: Mobeen Malik, Ying-Yu Chen, Martha F. Kienzle, Ronald G. Collman, Andrzej Ptasznik
Journal: Blood (2007)
The Guanylyl Cyclase Stlmulator Rloclguat Reduces Liver Fibrosis and Portal Pressure in Cirrhotic Rats
Authors: P. Schwabl, K. Brusilowska, F. Riedl, D. Bauer, B. Strobel, P. Supper, N. Rohr-Udilova, H. Hayden, B. Podesser, T. Reiberger, M. Trauner, M. Peck-Radosavljevic
Journal: Journal of Hepatology (2016)
Pruritus and Serum Autotaxin in Patients with Primary Biliary Cirrhosis Participating in the Poise Trial
Authors: A.E. Kremer, A.R. Bolier, E.S. Malecha, U. Beuers, M. Erickson, R. Hooshmand-Rad, D. Shapiro
Journal: Journal of Hepatology (2016)
PNPLA3 is Involved in Hepatic Lipids Metabolism through XBP1 and Modulation of Endoplasmic Reticulum Stress in Mice
Authors: M. Ono, T. Ochi, K. Munekage, M. Ogasawara, A. Hirose, Y. Nozaki-Fujimura, N. Okamoto, S. Iwasaki, J. Oben, T. Saibara
Journal: Journal of Hepatology (2016)
BAFF/Blys Levels Correlate with Disease Activity and Alter Peripheral B Cell Subsets in Patients with Chronic GVHD.
Authors: Stefanie Sarantopoulos, Kristen E. Stevenson, Haesook T. Kim, Nazmim S. Bhuiya, Corey S. Cutler, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz
Journal: Blood (2006)
The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri
Authors: Eric Van Cutsem, I Lang, G D'haens, Moiseyenko, J Zaluski, C Koehne, G Folprecht, Sabine Tejpar, Y Shparyk, M Schlichting, O Kisker, C Stroh, P Rougier
Journal: Annals of Oncology (2008)
Neutrophils Induce Early Hepatocyte Death by Contact Dependent and Independent Mechanisms and Positively Correlate with the Disease Outcome in Acute-On-Chronic Liver Failure
Authors: A. Khanam, N. Trehanpati, P. Riese, A. Rastogi, C.A. Guzman, S.K. Sarin
Journal: Journal of Hepatology (2016)
Effective Treatment of Resistant Hematological Malignancies by IL-2 Activated NK Cells Using Haploidentically Mismatched Donors by Induction of Graft-Versus-Tumor (GVT) Effect While Avoiding GVHD.
Authors: Shimon Slavin, Reuven Or, Aliza Ackerstein, Simcha Samuel, Michael Y. Shapira, Igor Resnick, Menachem Bitan, Memet Aker, Yael Gelfand, Osnat Eizik, Shoshana Morecki
Journal: Blood (2005)
What to Choose as Radical Local Treatment for Lung Metastases from Colo-Rectal Cancer: Surgery, Radiofrequency Ablation or Stereotactic Radiotherapy?
Authors: R. Schlijper, D. De Ruysscher, J.P. Grutters, R. Houben, A.C. Dingemans, J.E. Wildberger, D.V. Raemdonck, E. Van Cutsem, G. Lammering, P. Lambin
Journal: Annals of Oncology (2012)
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials
Authors: Edward K. Avila, Marc Chamberlain, David Schiff, Jaap C. Reijneveld, Terri S. Armstrong, Roberta Ruda, Patrick Y. Wen, Michael Weller, Johan A. F. Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R. MacDonald, Ryo Nishikawa, Aashit Shah, Charles J. Vecht, Paula Warren, Martin J. van den Bent, Lisa M. DeAngelis
Journal: Neuro-Oncology (2016)

Patients with low-grade glioma frequently have brain tumor–related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.
Effect of neratinib (N) alone and in combination with trastuzumab (T) in HER2-positive breast cancer (BC) cell lines.
Authors: Alexandra Canonici, Kasper Pedersen, Naomi Walsh, John Crown, Norma O'Donovan
Journal: Journal of Clinical Oncology (2012)

632 Background: HER-2, a member of the transmembrane receptor tyrosine kinase ErbB family, is over-expressed in approximately 25% of BC. HER-2 targeted therapies, in particular, T, a monoclonal antibody targeting HER-2, and lapatinib (L), a reversible HER-2 tyrosine kinase inhibitor, have been shown to significantly improve the prognosis for HER-2 positive BC patients. However, resistance to T and/or L is a significant clinical problem. The aim of this study is to assess the activity of N (HKI-272), an irreversible HER-2 tyrosine kinase inhibitor, in HER-2 overexpressing BC cell lines, including T and/or L resistant cells. Methods: Using proliferation assays, the effect of N was assessed alone and in combination with T in HER-2 positive BC cell lines, including T and/or L resistant cell lines. The effect of N on HER-2 and downstream signalling molecules, Erk and Akt, was determined by immunoblotting. Results: HER-2 positive BC cell lines, including T and/or L resistant cells, are sensitive to N alone with IC 50 values (concentration which inhibits 50% of growth) ranging from 1 to 280 nM. The combination of N and T has additive effects in SkBR3 and BT474 which are sensitive to T and also in SKBR3-Lwhich are resistant to L. In the cell lines HCC1954, HCC1954-L, MDA-MB-453, JIMT1 and SKBR3-HL which are resistant to T, combined treatment with T and N showed no enhancement compared to N alone. Finally, N decreased phosphorylation of HER-2, Erk and Akt in all cell lines tested. Conclusions: Our results suggest that N should be studied in patients with HER-2 positive BC, including patients with T and/or L resistant BC. We also demonstrate that N in combination with T may be more effective than either agent alone in T sensitive cells.
Insights in Dynamic Kinome Reprogramming As a Consequence of MEK Inhibition in MLL-Rearranged AML.
Authors: Kim R Kampen, Arja ter Elst, Sander H Diks, Frank JG Scherpen, Valerie De Haas, Maikel P Peppelenbosch, Evelina S. De Bont
Journal: Blood (2012)
Introducing JAMA Performance Improvement
Authors: Edward H. Livingston
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comment on Almurdhi et al. Reduced Lower-Limb Muscle Strength and Volume in Patients With Type 2 Diabetes in Relation to Neuropathy, Intramuscular Fat, and Vitamin D Levels. Diabetes Care 2016;39:441–447
Authors: Guillaume Treiber, Laurence Baillet-Blanco, Marie Hugo, Emilie Pupier, Isabelle Redonnet-Vernhet, Sophie Cambos, Vincent Rigalleau
Journal: Diabetes Care (2016)

We were very interested by the recent article by Almurdhi et al. (1) that reported a reduction of lower-limb strength in patients with type 2 diabetes mellitus (T2DM) and neuropathy. Unexpectedly, the authors did not detect any relation between the reduced muscle strength and the 25-hydroxyvitamin D levels. We wondered whether another modifiable factor, the treatment with statins, may play a role in lower-limb weakness and neuropathy in these patients.

We are presently researching whether any modifiable superimposed factor may contribute to neuropathy in patients with T2DM. In …
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Authors: Laura Q.M. Chow, Robert Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph Paul Eder, Barbara Burtness, Se-Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia-Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled-Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert
Journal: Journal of Clinical Oncology (2016)

Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported. Patients and Methods Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pembrolizumab 200 mg intravenously once every 3 weeks. Imaging was performed every 8 weeks. Primary end points were overall response rate (ORR) per central imaging vendor (Response Evaluation Criteria in Solid Tumors v1.1) and safety. Secondary end points included progression-free survival, overall survival, and association of response and PD-L1 expression. Patients who received one or more doses of pembrolizumab were included in analyses. Results Of 132 patients enrolled, median age was 60 years (range, 25 to 84 years), 83% were male, and 57% received two or more lines of therapy for R/M disease. ORR was 18% (95% CI, 12 to 26) by central imaging vendor and 20% (95% CI, 13 to 28) by investigator review. Median duration of response was not reached (range, ≥ 2 to ≥ 11 months). Six-month progression-free survival and overall survival rates were 23% and 59%, respectively. By using tumor and immune cells, a statistically significant increase in ORR was observed for PD-L1-positive versus -negative patients (22% v 4%; P = .021). Treatment-related adverse events of any grade and grade ≥ 3 events occurred in 62% and 9% of patients, respectively. Conclusion Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.
An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations
Authors: K.H. Weiss, A. Ala, F. Askari, D. Bega, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, M. Schilsky
Journal: Journal of Hepatology (2016)
Systems Level Analysis for Characterization of Genes Responsible for Outcome in Severe Alcoholic Hepatitis Patients on Steroid Therapy
Authors: S.K. Sharma, J.S. Maras, S. Hussain, S. Das, V. Khillan, S.M. Shasthry, C.B. Sharma, C. Junot, R. Moreau, S.K. Sarin
Journal: Journal of Hepatology (2016)